Researchers from Okayama University have developed a method to treat the congenital heart defect known as hypoplastic left heart syndrome [HLHS] by utilizing a specialized cardiac stem cell. In a Phase I clinical trial conducted on children suffering from HLHS, the scientists concluded that, because the young stem cells in children are more abundant and self-renewing than those in adults, intracoronary injection of stem cells is a safe and feasible approach to treating the condition. Continue reading
A team of bioengineers from Tel Aviv University is currently developing a scaffold to help regenerate heart muscle through the use of autologous stem cells. The scientists, led by Dr. Tal Dvir, aim to replace damaged cardiac tissue in heart attack patients by creating a scaffold out of collagen and gold nanoparticles, and then infusing it with the patient’s own stem cells to stimulate the rejuvenation of cardiomyocytes. Continue reading
As reported on the front page of the New York Times Science section, clinical applications of stem cell based therapies are accelerating at a rate that will revolutionize the medical field in a matter of years. In the United States alone, there are currently over 4000 therapies in clinical trials for the treatment of heart disease, blindness, spinal cord injuries, diabetes, H.I.V., and other diseases, injuries, and traumas. Continue reading
A team of researchers led by Dr. Gordana Vunjak-Novakovic [a member of StemSave’s Scientific Advisory Council] has engineered a scaffold to facilitate the regeneration of heart muscle through the use of adult stem cells. In an animal model, Vunjak-Novakovic and her team created a scaffold using biodegradable chitosan and carbon nanofibers, infusing it with stem cells to provoke the regeneration of beating cardiomyocytes. Continue reading
Research teams from Cedars-Sinai Heart Institute and the Minneapolis Heart Institute with funding from CIRM [California Institute for Regenerative Medicine] are moving to Phase 2 Clinical Trials for a treatment that utilizes cardiac stem cells to repair severe heart damage. The treatment development was led by Eduardo Marbán, a director at the Cedars-Sinai Heart Institute and founder of Capricor. This groundbreaking treatment involves the injection of stem cells into the coronary artery, which then migrate to the heart and promote the regrowth of healthy heart muscle. Continue reading
Researchers from the University of Vermont have developed a novel and effective application of mesenchymal stem cells [the same type found in Dental Stem Cells] to treat heart disease. The MSCs, when transplanted along with cardiac stem cells into the heart [in an animal model], produced a “cocktail” of protective ligands that improved the grafting success of the cardiac stem cells. Continue reading
Utilizing autologous [the patient’s own]stem cells to regenerate heart muscle, scientists at the Novant Health Group have successfully treated patients that suffered from severe heart attacks; potentially limiting the long term loss of tissue and preserving heart function for victims. The patient’s own mesenchymal stem cells [the same type as dental stem cells] are harvested and then implanted back into the damaged area, where they recruit surrounding cells to aid in the repair process. Continue reading
Mayo Clinic researchers from the Center of Regenerative Medicine have utilized a patient’s own stem cells in a novel treatment for heart disease. The treatment involves harvesting the patient’s own stem cells, expanding and differentiating them in-vitro [outside the body] and transplanting them back into the patient. As a result of the successful initial study, a wider clinical trial is planned.
Mayo Clinic researchers have resynchronized a disrupted heartbeat by using stem cells. Dr. Andre Terzic, a senior author of the study explained, “By harnessing the potential of regenerative medicine – repairing the injured heart, in this case – we will be increasingly able to provide more definitive solutions to our patients”.
Hypoxic-Ischemic brain injury can be caused by a number of ailments including cardiac arrest (heart attack), respiratory arrest, incomplete suffocation and more. The incidence in the United States of hypoxic-ischemic brain injuries is 1-8 in every 1000 births. Researchers at Nagoya University have used stem cells from human exfoliated deciduous teeth (SHED) to treat neonatal mice with hypoxic-ischemic brain injuries. They have found that this treatment leads to neurological and pathophysiological recovery of these injuries. These finding indicate that SHED may be utilized in the future for a novel neuroprotective therapy for hypoxic-ischemic brain injuries.